Selectivity matters
Filgotinib is a highly selective JAK1 inhibitor

**Ratio JAK1/JAK2 in human whole blood assay**

Hb recovery[1]

anemia

baricitinib   tofacitinib   upadacitinib   filgotinib

1: A Pardanani, et al, Leukemia (2013) 27, 1322–1327

Galápagos

Hemoglobin
EPO-JAK2 selectivity

Hb mean CFB (g/dL), W12

Monitoring required

Galápagos

NK cells
IL15 - JAK3 selectivity

NK cells mean CFB (%), W12

filgotinib: pbo, 100mg qd, 200mg qd

baricitinib*: pbo, 2mg qd, 4mg qd

tofacitinib**: pbo, 5mg bid, 15mg bid

Monitoring total lymphocytes required

upadacitinib: pbo, 6mg bid, 12mg bid, 18mg bid

Galápagos

Herpes zoster
IFN-driven

Herpes zoster cases (%)

Galápagos

Lipid improvement
JAK1-selectivity

LDL/HDL mean CFB, W12, inversed

	pbo	100mg qd	200mg qd	pbo	2mg qd	4mg qd	pbo	5mg bid	10mg bid	pbo	6mg bid	12mg bid	18mg bid
value	-0.05	-0.03	-0.27	-0.02	-0.02	0.00	-0.01	0.03	0.02	0.05	0.14	0.06	

| filgotinib | baricitinib | tofacitinib | upadacitinib |

Galápagos